Cytoreductive nephrectomy in the era of targeted therapies: a review

被引：25

作者：

Pindoria, Nisha ^{[1
]}

Raison, Nicholas ^{[1
]}

Blecher, Gideon ^{[1
]}

Catterwell, Rick ^{[1
]}

Dasgupta, Prokar ^{[1
]}

机构：

[1] Guys Hosp, Urol Ctr, London SE1 9RT, England

来源：

BJU INTERNATIONAL | 2017年 / 120卷 / 03期

基金：

英国医学研究理事会;

关键词：

cytoreductive nephrectomy; immunotherapy; targeted therapy; metastatic renal cell carcinoma; RENAL-CELL CARCINOMA; NEPHRON-SPARING SURGERY; INTERFERON-ALPHA; SURGICAL-MANAGEMENT; PLANNED NEPHRECTOMY; PATIENT SURVIVAL; SUNITINIB; REGRESSION; COMBINATION; IMPACT;

D O I：

10.1111/bju.13860

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

In the pre-targeted therapy era, palliative cytoreductive nephrectomy combined with cytokine immunotherapy was the standard treatment protocol for the management of metastatic renal cell carcinoma. The introduction of targeted therapies has improved response rates, median survival and overall prognosis when compared to immunotherapy. The role of cytoreductive nephrectomy in providing an independent survival advantage when used alongside immunotherapy has been demonstrated by two randomised controlled trials. However, with the new shift in improved treatment outcomes from cytokine immunotherapy to targeted therapies, the continuing role of cytoreductive nephrectomy as a viable surgical treatment method remains controversial.

引用

页码：320 / 328

页数：9

共 68 条

[1] Initial Series of Robotic Radical Nephrectomy with Vena Caval Tumor Thrombectomy [J].